Zimislecel

N/A

Report date: 2025/01/21 17:01:28
First In Class

Base Information

Drug NameZimislecel
Drug Alias NameAllogeneic human stem cell-derived islet cell therapy (Vertex Pharmaceuticals)Stem cell-derived beta cells(Vertex Pharmaceuticals)Stem cell-derived fully differentiated pancreatic islet cell therapy(Vertex Pharmaceuticals)VX-880STx-02
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Somatic cell > Pancreatic islet cell therapyCell and gene therapy > Cell therapy > Source of cells > Embryonic stem cell-derived
Mechanisms of ActionPancreatic beta cell replacements
TargetsNot applicable
Therapy Area/IndicationsRejection of renal transplantationAwarenessHypoglycemia +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[10] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesStevia Pharma
China Registration ClassN/A

Develop Information

Active CompaniesLonzaVertex Pharmaceuticals Incorporated
Inactive CompaniesN/A
Active IndicationsRejection of renal transplantationAwarenessHypoglycemia +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A